Document is current
Any future updates will be listed below
-
Authors
Jiang, Peng https://orcid.org/0000-0002-7828-5486
Zhang, Yu
Ru, Beibei https://orcid.org/0000-0003-3897-7733
Yang, Yuan
Vu, Trang
Paul, Rohit
Mirza, Amer
Altan-Bonnet, Grégoire https://orcid.org/0000-0002-7283-3162
Liu, Lingrui
Ruppin, Eytan
Wakefield, Lalage
Wucherpfennig, Kai W. https://orcid.org/0000-0002-1829-302X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Intramural Research Budget)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K12HL138037)
U.S. Department of Health & Human Services | National Institutes of Health (P01 CA163222)
- License Information
-
More Information
Article History
Received: 3 March 2021
Accepted: 17 August 2021
First Online: 30 September 2021
Competing interests
: K.W.W. is cofounder of Immunitas Therapeutics and also serves as the advisory board member of Immunitas Therapeutics, TCR2 Therapeutics, T-Scan Therapeutics, S.Q.Z. Biotech and Nextech Invest. K.W.W. received sponsored research funding from Novartis. The other authors declare no competing interests.
Free to read: This content has been made available to all.
